Home » Stocks » PRTC

PureTech Health PLC (PRTC)

Stock Price: $52.00 USD -3.50 (-6.31%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $49.78 -2.22 (-4.27%) Jan 22, 4:35 PM
Market Cap 1.46B
Revenue (ttm) 9.81M
Net Income (ttm) 366.07M
Shares Out 285.74M
EPS (ttm) 14.40
PE Ratio 3.61
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $52.00
Previous Close $55.50
Change ($) -3.50
Change (%) -6.31%
Day's Open 54.08
Day's Range 49.78 - 55.49
Day's Volume 987
52-Week Range 38.50 - 60.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative.

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative.

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--PureTech (Nasdaq: PRTC) initiated a global, Phase 2 trial of LYT-100 (deupirfenidone) in Long COVID respiratory complications and related sequelae.

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

About PRTC

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a ... [Read more...]

Industry
Biotechnology
CEO
Daphne Zohar
Employees
300
Stock Exchange
NASDAQ
Ticker Symbol
PRTC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for PRTC is 66.33, which is an increase of 27.56% from the latest price.

Price Target
$66.33
(27.56% upside)